Tillkännagivande • Jun 30
Liaoning Oxiranchem,Inc. to Report First Half, 2026 Results on Aug 25, 2026 Liaoning Oxiranchem,Inc. announced that they will report first half, 2026 results on Aug 25, 2026 Tillkännagivande • Apr 28
Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026 Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China Tillkännagivande • Mar 31
Liaoning Oxiranchem,Inc. to Report Q1, 2026 Results on Apr 28, 2026 Liaoning Oxiranchem,Inc. announced that they will report Q1, 2026 results on Apr 28, 2026 Tillkännagivande • Dec 31
Liaoning Oxiranchem,Inc. to Report Fiscal Year 2025 Results on Apr 28, 2026 Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2025 results on Apr 28, 2026 Tillkännagivande • Sep 30
Liaoning Oxiranchem,Inc. to Report Q3, 2025 Results on Oct 27, 2025 Liaoning Oxiranchem,Inc. announced that they will report Q3, 2025 results on Oct 27, 2025 Tillkännagivande • Sep 12
Liaoning Oxiranchem,Inc. Approves Board Appointments Liaoning Oxiranchem,Inc. at its EGM held on September 10, 2025, approved the appointment of Ren Jiangang and Liu Guocheng as independent directors. Tillkännagivande • Jul 02
Liaoning Oxiranchem,Inc. to Report First Half, 2025 Results on Aug 26, 2025 Liaoning Oxiranchem,Inc. announced that they will report first half, 2025 results on Aug 26, 2025 Tillkännagivande • Apr 22
Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025 Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning China Tillkännagivande • Mar 31
Liaoning Oxiranchem,Inc. to Report Q1, 2025 Results on Apr 22, 2025 Liaoning Oxiranchem,Inc. announced that they will report Q1, 2025 results on Apr 22, 2025 Tillkännagivande • Dec 31
Liaoning Oxiranchem,Inc. to Report Fiscal Year 2024 Results on Apr 22, 2025 Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2024 results on Apr 22, 2025 Reported Earnings • Oct 28
Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.061 loss in 3Q 2023) Third quarter 2024 results: CN¥0.05 loss per share (improved from CN¥0.061 loss in 3Q 2023). Revenue: CN¥1.17b (up 24% from 3Q 2023). Net loss: CN¥32.7m (loss narrowed 25% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Tillkännagivande • Sep 30
Liaoning Oxiranchem,Inc. to Report Q3, 2024 Results on Oct 28, 2024 Liaoning Oxiranchem,Inc. announced that they will report Q3, 2024 results on Oct 28, 2024 New Risk • Sep 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Reported Earnings • Aug 06
Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.13 loss in 2Q 2023) Second quarter 2024 results: CN¥0.032 loss per share (improved from CN¥0.13 loss in 2Q 2023). Revenue: CN¥1.08b (down 2.1% from 2Q 2023). Net loss: CN¥22.4m (loss narrowed 75% from 2Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Tillkännagivande • Jun 29
Liaoning Oxiranchem,Inc. to Report First Half, 2024 Results on Aug 06, 2024 Liaoning Oxiranchem,Inc. announced that they will report first half, 2024 results on Aug 06, 2024 Reported Earnings • Apr 24
First quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.09 loss in 1Q 2023) First quarter 2024 results: CN¥0.12 loss per share (further deteriorated from CN¥0.09 loss in 1Q 2023). Revenue: CN¥757.1m (down 19% from 1Q 2023). Net loss: CN¥78.4m (loss widened 30% from 1Q 2023). Tillkännagivande • Apr 23
Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024 Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning China New Risk • Apr 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Tillkännagivande • Mar 30
Liaoning Oxiranchem,Inc. to Report Q1, 2024 Results on Apr 23, 2024 Liaoning Oxiranchem,Inc. announced that they will report Q1, 2024 results on Apr 23, 2024 New Risk • Mar 21
New major risk - Revenue and earnings growth Earnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Tillkännagivande • Dec 30
Liaoning Oxiranchem,Inc. to Report Fiscal Year 2023 Results on Apr 23, 2024 Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2023 results on Apr 23, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: CN¥0.061 loss per share (vs CN¥0.067 loss in 3Q 2022) Third quarter 2023 results: CN¥0.061 loss per share. Revenue: CN¥949.3m (down 35% from 3Q 2022). Net loss: CN¥43.6m (loss widened 12% from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Reported Earnings • Aug 29
Second quarter 2023 earnings released: CN¥0.13 loss per share (vs CN¥0.074 loss in 2Q 2022) Second quarter 2023 results: CN¥0.13 loss per share (further deteriorated from CN¥0.074 loss in 2Q 2022). Revenue: CN¥1.10b (down 30% from 2Q 2022). Net loss: CN¥89.8m (loss widened 73% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Reported Earnings • Apr 19
Full year 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.52 in FY 2021) Full year 2022 results: EPS: CN¥0.01 (down from CN¥0.52 in FY 2021). Revenue: CN¥5.64b (down 16% from FY 2021). Net income: CN¥5.60m (down 98% from FY 2021). Profit margin: 0.1% (down from 5.2% in FY 2021). Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥10.05, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 6.5% over the past year. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 29
Third quarter 2022 earnings released: CN¥0.031 loss per share (vs CN¥0.16 profit in 3Q 2021) Third quarter 2022 results: CN¥0.031 loss per share (down from CN¥0.16 profit in 3Q 2021). Revenue: CN¥1.46b (down 22% from 3Q 2021). Net loss: CN¥39.0m (down 136% from profit in 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Board Change • Oct 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥11.15, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Chemicals industry in China. Reported Earnings • Aug 24
Second quarter 2022 earnings released: CN¥0.074 loss per share (vs CN¥0.043 profit in 2Q 2021) Second quarter 2022 results: CN¥0.074 loss per share (down from CN¥0.043 profit in 2Q 2021). Revenue: CN¥1.58b (down 9.0% from 2Q 2021). Net loss: CN¥52.0m (down 261% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 22%, compared to a 42% growth forecast for the Chemicals industry in China. Reported Earnings • Apr 30
First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.08 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.08 in 1Q 2021). Revenue: CN¥1.34b (down 3.1% from 1Q 2021). Net income: CN¥99.7m (up 95% from 1Q 2021). Profit margin: 7.4% (up from 3.7% in 1Q 2021). The increase in margin was driven by lower expenses. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 18
Full year 2021 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in FY 2020) Full year 2021 results: EPS: CN¥0.53 (down from CN¥0.59 in FY 2020). Revenue: CN¥6.72b (up 18% from FY 2020). Net income: CN¥357.2m (down 11% from FY 2020). Profit margin: 5.3% (down from 7.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 26%, compared to a 48% growth forecast for the industry in China. Board Change • Dec 10
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. 
